SR9011
Metabolic / Fat LossAlso known as: SR-9011
Mechanism
SR9011 is an improved analog of SR9009 with higher potency at Rev-Erb-alpha receptors. Like SR9009, it modulates circadian metabolic pathways to increase fat oxidation and energy expenditure. It was also identified in cancer research for its ability to induce apoptosis in tumor cells by disrupting the oncogenic circadian transcriptional program.
Technical detail
SR9011 is a synthetic Rev-Erbα/β dual agonist with improved potency (EC50 ~790 nM for Rev-Erbα, ~560 nM for Rev-Erbβ) compared to SR9009. Beyond metabolic effects shared with SR9009 (lipogenesis suppression, fatty acid oxidation enhancement, mitochondrial biogenesis), SR9011 has been studied for its selective cytotoxicity against cancer cells, including glioblastoma and leukemia. Cancer cells exhibit disrupted circadian regulation and increased dependence on circadian transcription for survival, making them selectively vulnerable to Rev-Erb activation-induced apoptosis and autophagy.